Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Subcutaneous Ianalumab in Autoimmune Disease
NCT06293365Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of ianalumab in rheumatoid arthritis (RA), Sjögren's syndrome, systemic lupus erythematosus (SLE), sponsored by Novartis. Started Jul 2024; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
rheumatoid arthritis (RA)Sjögren's syndromesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06293365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293365.